Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early extra measles immunisation during a measles outbreak
ISRCTN61052983Phase 4Not yet recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jul 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of measles, mumps, and rubella vaccine in measles (2 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Measles-specific virus-neutralising antibody concentrations 4 weeks after MMR-0 immunisation. Planned start Jul 2028; status: not yet recruiting.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
measles
Beyond the preview
Go deeper on ISRCTN61052983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN61052983.